137 related articles for article (PubMed ID: 16254790)
1. Inflammation 2005 - Seventh World Congress. Rheumatoid arthritis and cell signaling.
Parnham MJ
IDrugs; 2005 Oct; 8(10):786-8. PubMed ID: 16254790
[TBL] [Abstract][Full Text] [Related]
2. Inflammation 2005 - Seventh World Congress. Highlights II.
Enefer S
IDrugs; 2005 Oct; 8(10):791-2. PubMed ID: 16254792
[No Abstract] [Full Text] [Related]
3. Inflammation 2005 - Seventh World Congress. Highlights I.
Enefer S
IDrugs; 2005 Oct; 8(10):788-90. PubMed ID: 16254791
[No Abstract] [Full Text] [Related]
4. [Interleukin-6 in pathogenesis of rheumatoid arthritis].
Mihara M; Nishimoto N
Nihon Rinsho; 2005 Jan; 63 Suppl 1():158-62. PubMed ID: 15799337
[No Abstract] [Full Text] [Related]
5. [Adhesion molecule in pathogenesis of rheumatoid arthritis].
Origuchi T; Eguchi K
Nihon Rinsho; 2005 Jan; 63 Suppl 1():200-7. PubMed ID: 15799346
[No Abstract] [Full Text] [Related]
6. Technology evaluation: abatacept, Bristol-Myers Squibb.
Dumont FJ
Curr Opin Mol Ther; 2004 Jun; 6(3):318-30. PubMed ID: 15264435
[TBL] [Abstract][Full Text] [Related]
7. Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy.
Tas SW; Remans PH; Reedquist KA; Tak PP
Curr Pharm Des; 2005; 11(5):581-611. PubMed ID: 15720277
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction in rheumatoid arthritis.
Piecyk M; Anderson P
Best Pract Res Clin Rheumatol; 2001 Dec; 15(5):789-803. PubMed ID: 11812022
[TBL] [Abstract][Full Text] [Related]
9. [Abnormal gp130 signaling and autoimmune disease].
Ishihara K; Atsumi T
Tanpakushitsu Kakusan Koso; 2002 Dec; 47(16 Suppl):2336-42. PubMed ID: 12518458
[No Abstract] [Full Text] [Related]
10. New therapies for treatment of rheumatoid arthritis.
Smolen JS; Aletaha D; Koeller M; Weisman MH; Emery P
Lancet; 2007 Dec; 370(9602):1861-74. PubMed ID: 17570481
[TBL] [Abstract][Full Text] [Related]
11. The role of Toll-like receptor signalling in the pathogenesis of arthritis.
Brentano F; Kyburz D; Schorr O; Gay R; Gay S
Cell Immunol; 2005 Feb; 233(2):90-6. PubMed ID: 15963480
[TBL] [Abstract][Full Text] [Related]
12. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
Scheinfeld N
J Dermatolog Treat; 2006; 17(4):229-34. PubMed ID: 16971318
[TBL] [Abstract][Full Text] [Related]
13. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
[TBL] [Abstract][Full Text] [Related]
14. Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?
Caporali R; Bugatti S; Cavagna L; Antivalle M; Sarzi-Puttini P
Autoimmun Rev; 2014 Jan; 13(1):49-53. PubMed ID: 23777823
[TBL] [Abstract][Full Text] [Related]
15. Early inflammatory arthritis versus rheumatoid arthritis.
Finckh A
Curr Opin Rheumatol; 2009 Mar; 21(2):118-23. PubMed ID: 19339921
[TBL] [Abstract][Full Text] [Related]
16. [New biological therapeutic options for the treatment of RE: inhibition of costimulatory molecules and blockade of Interleukin-6-interaction].
Perniok A; Rubbert-Roth A
Z Rheumatol; 2003 Oct; 62(5):433-8. PubMed ID: 14579030
[TBL] [Abstract][Full Text] [Related]
17. Role of abatacept in the management of rheumatoid arthritis.
Nogid A; Pham DQ
Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
[TBL] [Abstract][Full Text] [Related]
18. CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.
Cutolo M; Sulli A; Paolino S; Pizzorni C
Expert Rev Clin Immunol; 2016; 12(4):417-25. PubMed ID: 26679631
[TBL] [Abstract][Full Text] [Related]
19. Cutting edge: CTLA-4 (CD152) differentially regulates mitogen-activated protein kinases (extracellular signal-regulated kinase and c-Jun N-terminal kinase) in CD4+ T cells from receptor/ligand-deficient mice.
Schneider H; Mandelbrot DA; Greenwald RJ; Ng F; Lechler R; Sharpe AH; Rudd CE
J Immunol; 2002 Oct; 169(7):3475-9. PubMed ID: 12244135
[TBL] [Abstract][Full Text] [Related]
20. Technology evaluation: Belatacept, Bristol-Myers Squibb.
Vanhove B; Soulillou JP
Curr Opin Mol Ther; 2005 Aug; 7(4):384-93. PubMed ID: 16121705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
